Document is current
Any future updates will be listed below
-
Authors
Riaz, Irbaz Bin https://orcid.org/0000-0003-4249-0311
Naqvi, Syed Arsalan Ahmed
Ashraf, Noman
Harris, Gordon J.
Kehl, Kenneth L.
- License Information
-
More Information
Article History
Received: 9 July 2024
Accepted: 12 April 2025
First Online: 10 June 2025
Competing interests
: I.B.R., S.A.A.N., N.A., K.L.K. do not report any disclosures relevant to this work. G.J.H. serves as the co-founder, chief science officer, and board member, Yunu, Inc and serves on the scientific advisory board, Fovia, Inc.
: This study was approved by the Institutional Review Board at Dana-Farber/Harvard Cancer Center (IRB protocol #16-360; Strategic and Analytic Approach to Collecting Clinical and Outcomes Data and Derived Molecular Features for Annotating Profile Results). There was a waiver of informed consent given the minimal risk to patients of the medical record review and the large cohort size, which would have precluded re-approaching each patient individually for this specific study.
